Immune checkpoint inhibitors (ICIs), targeting the programmed cell death 1 receptor (PD-1)/programmed cell death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) pathways, have transformed cancer treatment. This evidence concerns the gene CD274 and cancer.